Company Overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer treatment. The company operates within the oncology and biotechnology industries, with an emphasis on targeted therapies designed to address genetically defined cancers and to improve outcomes for patients with significant unmet medical needs. Kura’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, and financing activities, as the company has not yet commercialized a product based on publicly available filings through 2025. Its research programs primarily target kinase signaling pathways, menin interactions, and other molecular drivers associated with hematologic malignancies and solid tumors.

The company was founded in 2014 and is headquartered in San Diego, California. Kura evolved through the acquisition and advancement of targeted oncology assets, building a pipeline centered on precision oncology and combination therapy strategies. Its strategic positioning is tied to expertise in molecularly targeted cancer therapies and collaborations with larger pharmaceutical companies to support development and commercialization capabilities. Key pipeline programs have included ziftomenib, a menin inhibitor being developed for genetically defined acute leukemias, and tipifarnib, a farnesyl transferase inhibitor studied across several oncology indications.

Business Operations

Kura Oncology primarily operates as a single biotechnology business focused on oncology drug development, with research, clinical development, regulatory, and corporate operations centered in the United States while conducting multinational clinical trials. The company generates funding primarily through equity offerings, licensing agreements, milestone payments, and strategic collaborations rather than commercial product sales. Its core assets include internally developed and licensed oncology compounds, proprietary research capabilities, intellectual property portfolios, and clinical development infrastructure.

The company’s principal programs include ziftomenib and tipifarnib, alongside additional early-stage precision oncology candidates. Kura has maintained strategic partnerships with larger pharmaceutical companies to expand development and commercialization reach. Notably, the company entered into collaboration arrangements involving Kyowa Kirin Co., Ltd. related to tipifarnib and later established a global strategic collaboration with Kyowa Kirin focused on ziftomenib development and commercialization. Clinical development activities span multiple countries through collaborations with academic cancer centers, investigators, and contract research organizations.

Strategic Position & Investments

Kura Oncology’s strategic direction centers on advancing targeted therapies for molecularly defined cancers, particularly hematologic malignancies with identifiable genetic mutations. The company has emphasized precision medicine approaches, biomarker-driven clinical trials, and combination therapy strategies intended to improve efficacy and patient selection. Its development focus has increasingly prioritized menin inhibition through ziftomenib, especially in acute myeloid leukemia populations associated with NPM1 mutations and KMT2A rearrangements.

Major investments have been directed toward clinical trial expansion, regulatory engagement, manufacturing readiness, and pipeline diversification. The collaboration with Kyowa Kirin represented a significant strategic transaction intended to provide development capital, commercialization support, and broader geographic reach. Kura has also invested in research collaborations and intellectual property expansion related to targeted oncology therapeutics. The company’s involvement in emerging oncology sectors includes precision hematology, epigenetic regulation, and genetically targeted cancer therapies. Public disclosures indicate continued emphasis on advancing late-stage clinical assets while evaluating additional oncology opportunities aligned with its scientific platform.

Geographic Footprint

Kura Oncology is headquartered in San Diego, California, and its operational base is primarily concentrated in the United States. However, the company maintains an international clinical development footprint through multicenter clinical trials conducted across North America, Europe, and parts of the Asia-Pacific region. Its partnerships and investigator networks support global patient enrollment and regulatory engagement in multiple jurisdictions.

Through collaborations such as those with Kyowa Kirin, Kura has expanded its international operational influence and potential commercialization reach, particularly in Japan and other international oncology markets. While the company does not maintain the extensive global infrastructure of large pharmaceutical firms, its development programs are designed for worldwide regulatory and commercial applicability in targeted oncology indications.

Leadership & Governance

Kura Oncology was co-founded by oncology-focused biotechnology executives and scientists with experience in targeted cancer drug development. The company’s leadership strategy has consistently emphasized scientific rigor, precision medicine, and disciplined clinical execution. Public corporate communications and filings describe a governance approach centered on advancing differentiated oncology therapies through strategic partnerships, data-driven development, and regulatory engagement.

Key executives include:

• Troy E. Wilson – President, Chief Executive Officer, and Chairman
• Mollie Leoni – Chief Financial Officer
• Thomas P. Doyle – Chief Legal Officer
• Dario C. Altieri – Chief Scientific Officer
• Stephen Dale – Chief Business Officer
• John A. Josey – Chief Medical Officer

The company’s board and executive leadership include individuals with backgrounds in biotechnology, oncology research, pharmaceutical development, and corporate governance. Leadership communications in public filings and investor materials consistently emphasize advancing precision oncology therapies through strategic collaborations, disciplined capital allocation, and clinically differentiated development programs.